• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

作者信息

Kater Arnon P, Tonino Sanne H, Spiering Marjolein, Chamuleau Martine E D, Liu Roberto, Adewoye Adeboye Henry, Gao Jie, Dreiling Lyndah, Xin Yan, Doorduijn Jeanette K, Kersten Marie José

机构信息

Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.

Lymphoma and Myeloma Center (LYMMCARE), Academic Medical Center, Amsterdam, The Netherlands.

出版信息

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x.

DOI:10.1038/s41408-018-0055-x
PMID:29434192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5809482/
Abstract
摘要

相似文献

1
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.PI3Kδ抑制剂阿卡利西布（GS-9820）治疗复发/难治性淋巴系统恶性肿瘤的1b期安全性和有效性研究的最终结果。
Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x.
2
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.PI3K抑制剂在B细胞淋巴瘤中的临床应用：现状与未来。
Expert Rev Anticancer Ther. 2017 Mar;17(3):271-279. doi: 10.1080/14737140.2017.1285702. Epub 2017 Feb 6.
3
PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).PI3Kδ 抑制剂在癌症治疗中的应用：专利研究综述（2015 年至今）。
Expert Opin Ther Pat. 2019 Dec;29(12):925-941. doi: 10.1080/13543776.2019.1687685. Epub 2019 Nov 7.
4
Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.PTEN 缺陷型造血肿瘤细胞的增殖不受 p110 PI3 激酶亚型选择性抑制的影响，且需要阻断所有 1 类 PI3K 活性。
Br J Haematol. 2013 Jul;162(2):285-9. doi: 10.1111/bjh.12353. Epub 2013 Apr 18.
5
Duvelisib, a new PI3K inhibitor for lymphoid malignancies.度维利塞，一种用于治疗淋巴系统恶性肿瘤的新型PI3K抑制剂。
Clin Adv Hematol Oncol. 2020 Oct;18(10):606-608.
6
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice.淋巴肿瘤患者使用生物类似药非格司亭的门诊经验：日常临床实践中的经验教训
Hematol Oncol. 2017 Dec;35(4):918-920. doi: 10.1002/hon.2371. Epub 2016 Nov 10.
7
Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms.造血和淋巴肿瘤中的赖氨酸特异性去甲基化酶1（LSD1）
Blood. 2014 Jul 3;124(1):151-2. doi: 10.1182/blood-2014-04-569525.
8
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.双重SYK/JAK抑制剂塞杜替尼治疗复发或难治性B细胞恶性肿瘤患者的疗效和安全性：一项I期研究结果
Am J Hematol. 2019 Apr;94(4):E90-E93. doi: 10.1002/ajh.25387. Epub 2019 Jan 8.
9
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.idelalisib：用于治疗慢性淋巴细胞白血病、小淋巴细胞白血病和滤泡性淋巴瘤的首款PI3Kδ抑制剂。
Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10.
10
New drugs and pharmacological interactions in real life.真实生活中的新药和药物相互作用。
Hematol Oncol. 2021 Jun;39 Suppl 1:78-82. doi: 10.1002/hon.2859.

引用本文的文献

1
Fluorinated small molecule derivatives in cancer immunotherapy: emerging frontiers and therapeutic potential.癌症免疫治疗中的氟化小分子衍生物：新兴前沿与治疗潜力
Front Immunol. 2025 Jul 18;16:1622091. doi: 10.3389/fimmu.2025.1622091. eCollection 2025.
2
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.针对癌症治疗中小分子抑制剂的 PI3K 家族：当前临床现状和未来方向。
Mol Cancer. 2024 Aug 10;23(1):164. doi: 10.1186/s12943-024-02072-1.
3
Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.

本文引用的文献

1
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.静脉注射泛I类磷脂酰肌醇3激酶抑制剂库潘尼西（BAY 80-6946）用于晚期实体瘤和非霍奇金淋巴瘤患者的首次人体I期研究。
Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.
2
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.一线使用idelalisib治疗慢性淋巴细胞白血病会频繁引发免疫介导的肝毒性。
Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.
3
靶向抑制 PI3K/Akt/mTOR 信号通路：肉瘤治疗的潜力。
Mini Rev Med Chem. 2024;24(16):1496-1520. doi: 10.2174/0113895575270904231129062137.
4
Small molecule-based immunomodulators for cancer therapy.用于癌症治疗的基于小分子的免疫调节剂。
Acta Pharm Sin B. 2022 Dec;12(12):4287-4308. doi: 10.1016/j.apsb.2022.11.007. Epub 2022 Nov 12.
5
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.B细胞受体信号传导的调控及其在侵袭性B细胞淋巴瘤中的治疗意义
Cancers (Basel). 2022 Feb 9;14(4):860. doi: 10.3390/cancers14040860.
6
A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.磷酸肌醇 3 激酶 δ 亚型（PI3Kδ）及其抑制剂在恶性肿瘤中的研究进展。
Med Sci Monit. 2021 Oct 9;27:e932772. doi: 10.12659/MSM.932772.
7
Construction of -Boc-2-Alkylaminoquinazolin-4(3)-Ones via a Three-Component, One-Pot Protocol Mediated by Copper(II) Chloride that Spares Enantiomeric Purity.通过氯化铜介导的三组分一锅法构建 -Boc-2-烷基氨基喹唑啉-4(3)-酮，该方法可保留对映体纯度。
Adv Synth Catal. 2021 Mar 16;363(6):1638-1645. doi: 10.1002/adsc.202001279. Epub 2021 Feb 3.
8
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.慢性淋巴细胞白血病中PI3K抑制的经验教训、挑战及未来治疗机会
Cancers (Basel). 2021 Mar 13;13(6):1280. doi: 10.3390/cancers13061280.
9
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中下一代PI3K抑制剂的利弊
Onco Targets Ther. 2020 Sep 29;13:9679-9688. doi: 10.2147/OTT.S268899. eCollection 2020.
10
From Biology to Therapy: The CLL Success Story.从生物学到治疗：慢性淋巴细胞白血病的成功故事
Hemasphere. 2019 Feb 9;3(2):e175. doi: 10.1097/HS9.0000000000000175. eCollection 2019 Apr.
Management of adverse events associated with idelalisib treatment: expert panel opinion.
idelalisib治疗相关不良事件的管理：专家小组意见
Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19.
4
Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.同工型选择性磷脂酰肌醇 3-激酶抑制剂对破骨细胞的影响：对细胞骨架组织、存活和吸收的作用。
J Biol Chem. 2013 Dec 6;288(49):35346-57. doi: 10.1074/jbc.M113.507525. Epub 2013 Oct 16.
5
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.与苯丁酸氮芥相比，氟达拉滨一线治疗对晚期慢性淋巴细胞白血病老年患者并无显著益处。
Blood. 2009 Oct 15;114(16):3382-91. doi: 10.1182/blood-2009-02-206185. Epub 2009 Jul 15.
6
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.慢性淋巴细胞白血病诊断与治疗指南：慢性淋巴细胞白血病国际研讨会报告，更新美国国立癌症研究所工作组1996年指南
Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
7
Revised response criteria for malignant lymphoma.恶性淋巴瘤修订后的反应标准。
J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
8
Lymphoid malignancies: the dark side of B-cell differentiation.淋巴系统恶性肿瘤：B细胞分化的阴暗面
Nat Rev Immunol. 2002 Dec;2(12):920-32. doi: 10.1038/nri953.